StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) income statement

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.88+0.76 (+3.60%)

Close on Nov 18, 2026Market cap $6.99BP/E 44.7Yield –

Amneal Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
39.3%
Operating margin
14.6%
Net margin
5.0%
Return on equity, FY2025
-80.0%

Financial strength

Current ratio
2.20
Debt to equity
77.83
Debt to assets
68.1%
Cash to current liabilities
14.5%

Valuation

P/E ratio
44.7
Price to sales
2.24
Price to book
211.59
Dividend yield
–

See a number that looks wrong?